This Viewpoint discusses whether commonly occuring, sometimes divergent interpretations of new evidence’s validity and usefulness should be explained when experts and guideline committees provide recommendations for screening or treatment.
No takes yet. Share an insight, caveat, or question.
Bauchner et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: